

Filed: July 1, 2019

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.  
Petitioner,

v.

BIOGEN MA, INC.  
Patent Owner.

---

Patent No. 8,399,514

---

*Inter Partes* Review IPR2018-01403

---

**PETITIONER'S NOTICE OF DEPOSITION OF  
DANIEL WYNN, M.D., FACNS FAASM**

Pursuant to 37 C.F.R. § 42.53, Petitioner Mylan Pharmaceuticals Inc., hereby provides notice that it will cross-examine Dr. Daniel Wynn, a witness of Patent Owner Biogen MA, Inc. The cross-examination will begin at 9:00 a.m. on July 16, 2019 at the offices of Pepper Hamilton LLP, 501 Grant Street, Suite 300, Union Trust Building, Pittsburgh, PA 15219. The parties have agreed on this date and location for the cross-examination of Dr. Wynn.

The cross-examination will be recorded by stenographic means by a court reporter licensed to administer oaths, and will also be recorded using audio and/or visual means.

Respectfully submitted,

PERKINS COIE LLP

Dated: July 1, 2019

By: /s/ Emily J. Greb

Emily J. Greb  
Reg. No. 68,244  
Perkins Coie LLP  
33 East Main Street, Suite 201  
Madison, WI 53703  
Telephone: (608) 663-7494  
E-mail: EGreb@perkinscoie.com

## CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing PETITIONER'S NOTICE OF DEPOSITION OF DANIEL WYNN, M.D., FACNS FAASM was served electronically via e-mail as follows:

Patent Owner:

Barbara C. McCurdy  
Mark J. Feldstein  
Erin M. Sommers  
Pier D. DeRoo  
Finnegan, Henderson, Farabow, Garrett  
& Dunner, LLP  
901 New York Avenue, NW  
Washington, DC 20001  
(202) 408-4047  
barbara.mccurdy@finnegan.com  
mark.feldstein@finnegan.com  
erin.sommers@finnegan.com  
pier.deroo@finnegan.com

Dated: July 1, 2019

/s/ Emily J. Greb  
Emily J. Greb  
Reg. No. 68,244